Cargando…
Pharmacometric analyses and clinical evidence for brigatinib dosing in anaplastic lymphoma kinase‐positive non‐small cell lung cancer
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286636/ https://www.ncbi.nlm.nih.gov/pubmed/35350085 http://dx.doi.org/10.1111/bcp.15322 |
| _version_ | 1785061792850903040 |
|---|---|
| author | Gupta, Neeraj Hanley, Michael J. Sinha, Vikram |
| author_facet | Gupta, Neeraj Hanley, Michael J. Sinha, Vikram |
| author_sort | Gupta, Neeraj |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10286636 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-102866362023-06-23 Pharmacometric analyses and clinical evidence for brigatinib dosing in anaplastic lymphoma kinase‐positive non‐small cell lung cancer Gupta, Neeraj Hanley, Michael J. Sinha, Vikram Br J Clin Pharmacol Letters to the Editor John Wiley and Sons Inc. 2022-03-29 2022-08 /pmc/articles/PMC10286636/ /pubmed/35350085 http://dx.doi.org/10.1111/bcp.15322 Text en © 2022 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Letters to the Editor Gupta, Neeraj Hanley, Michael J. Sinha, Vikram Pharmacometric analyses and clinical evidence for brigatinib dosing in anaplastic lymphoma kinase‐positive non‐small cell lung cancer |
| title | Pharmacometric analyses and clinical evidence for brigatinib dosing in anaplastic lymphoma kinase‐positive non‐small cell lung cancer |
| title_full | Pharmacometric analyses and clinical evidence for brigatinib dosing in anaplastic lymphoma kinase‐positive non‐small cell lung cancer |
| title_fullStr | Pharmacometric analyses and clinical evidence for brigatinib dosing in anaplastic lymphoma kinase‐positive non‐small cell lung cancer |
| title_full_unstemmed | Pharmacometric analyses and clinical evidence for brigatinib dosing in anaplastic lymphoma kinase‐positive non‐small cell lung cancer |
| title_short | Pharmacometric analyses and clinical evidence for brigatinib dosing in anaplastic lymphoma kinase‐positive non‐small cell lung cancer |
| title_sort | pharmacometric analyses and clinical evidence for brigatinib dosing in anaplastic lymphoma kinase‐positive non‐small cell lung cancer |
| topic | Letters to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286636/ https://www.ncbi.nlm.nih.gov/pubmed/35350085 http://dx.doi.org/10.1111/bcp.15322 |
| work_keys_str_mv | AT guptaneeraj pharmacometricanalysesandclinicalevidenceforbrigatinibdosinginanaplasticlymphomakinasepositivenonsmallcelllungcancer AT hanleymichaelj pharmacometricanalysesandclinicalevidenceforbrigatinibdosinginanaplasticlymphomakinasepositivenonsmallcelllungcancer AT sinhavikram pharmacometricanalysesandclinicalevidenceforbrigatinibdosinginanaplasticlymphomakinasepositivenonsmallcelllungcancer |